183 related articles for article (PubMed ID: 20627738)
1. Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.
Yu QS; Holloway HW; Luo W; Lahiri DK; Brossi A; Greig NH
Bioorg Med Chem; 2010 Jul; 18(13):4687-93. PubMed ID: 20627738
[TBL] [Abstract][Full Text] [Related]
2. Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.
Barak D; Ordentlich A; Stein D; Yu QS; Greig NH; Shafferman A
Biochem J; 2009 Jan; 417(1):213-22. PubMed ID: 18729824
[TBL] [Abstract][Full Text] [Related]
3. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.
Zhan ZJ; Bian HL; Wang JW; Shan WG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1532-4. PubMed ID: 20144867
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment.
Komloova M; Musilek K; Dolezal M; Gunn-Moore F; Kuca K
Curr Med Chem; 2010; 17(17):1810-24. PubMed ID: 20345342
[TBL] [Abstract][Full Text] [Related]
6. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.
Yu Q; Holloway HW; Flippen-Anderson JL; Hoffman B; Brossi A; Greig NH
J Med Chem; 2001 Nov; 44(24):4062-71. PubMed ID: 11708910
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
[TBL] [Abstract][Full Text] [Related]
8. Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.
Galdeano C; Coquelle N; Cieslikiewicz-Bouet M; Bartolini M; Pérez B; Clos MV; Silman I; Jean L; Colletier JP; Renard PY; Muñoz-Torrero D
Molecules; 2018 Mar; 23(3):. PubMed ID: 29534488
[TBL] [Abstract][Full Text] [Related]
9. Novel potent pyridoxine-based inhibitors of AChE and BChE, structural analogs of pyridostigmine, with improved in vivo safety profile.
Strelnik AD; Petukhov AS; Zueva IV; Zobov VV; Petrov KA; Nikolsky EE; Balakin KV; Bachurin SO; Shtyrlin YG
Bioorg Med Chem Lett; 2016 Aug; 26(16):4092-4. PubMed ID: 27377327
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of carbamate-modified (-)-N(1)-phenethylnorphysostigmine derivatives as selective butyrylcholinesterase inhibitors.
Takahashi J; Hijikuro I; Kihara T; Murugesh MG; Fuse S; Tsumura Y; Akaike A; Niidome T; Takahashi T; Sugimoto H
Bioorg Med Chem Lett; 2010 Mar; 20(5):1721-3. PubMed ID: 20137941
[TBL] [Abstract][Full Text] [Related]
11. The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis.
Foldes FF; Smith JC
Ann N Y Acad Sci; 1966 Jan; 135(1):287-301. PubMed ID: 5221345
[No Abstract] [Full Text] [Related]
12. Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities.
Shinada M; Narumi F; Osada Y; Matsumoto K; Yoshida T; Higuchi K; Kawasaki T; Tanaka H; Satoh M
Bioorg Med Chem; 2012 Aug; 20(16):4901-14. PubMed ID: 22831800
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, evaluation and QSAR analysis of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors.
Takahashi J; Hijikuro I; Kihara T; Murugesh MG; Fuse S; Kunimoto R; Tsumura Y; Akaike A; Niidome T; Okuno Y; Takahashi T; Sugimoto H
Bioorg Med Chem Lett; 2010 Mar; 20(5):1718-20. PubMed ID: 20137934
[TBL] [Abstract][Full Text] [Related]
14. Pyridophens: binary pyridostigmine-aprophen prodrugs with differential inhibition of acetylcholinesterase, butyrylcholinesterase, and muscarinic receptors.
Leader H; Wolfe AD; Chiang PK; Gordon RK
J Med Chem; 2002 Feb; 45(4):902-10. PubMed ID: 11831902
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of cholinesterase inhibitors.
Aquilonius SM; Hartvig P
Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
[TBL] [Abstract][Full Text] [Related]
16. [Current treatment of myasthenia gravis].
de Assis JL
Rev Paul Med; 1965 Oct; 67(4):231-42. PubMed ID: 5848156
[No Abstract] [Full Text] [Related]
17. Myasthenia gravis and glycopyrrolate.
Marcus E; Wayne F
S Afr Med J; 1981 Oct; 60(17):650. PubMed ID: 7302713
[No Abstract] [Full Text] [Related]
18. Cholinesterase inhibitors in myasthenia gravis.
Lange MJ
Practitioner; 1966 Mar; 196(173):448-53. PubMed ID: 5905423
[No Abstract] [Full Text] [Related]
19. Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.
Saifina LF; Abdalla M; Gubaidullina LM; Zueva IV; Eltayb WA; El-Arabey AA; Kharlamova AD; Lenina OA; Semenov VE; Petrov KA
Eur J Med Chem; 2023 Jan; 246():114949. PubMed ID: 36462442
[TBL] [Abstract][Full Text] [Related]
20. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.
Katz NK; Barohn RJ
Neuropharmacology; 2021 Jan; 182():108303. PubMed ID: 32918950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
